Email Updates

Search form

You are here


Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. TDF/FTC is approved for use as oral PrEP in a handful of countries but, for maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

A Kenyan public health expert, Dr. Peter Cherutich, has this opinion piece on the power of PrEP to impact Kenya’s HIV epidemic. Published in Kenya’s Standard Digital.

May 26, 2017
Standard Digital

The CDC and the WHO recommend a different number of days to be on PrEP before the drug is considered fully protective against HIV. This story from the looks at the reasons behind the discrepancy and how providers are advising their patients.

May 2, 2017

EurekAlert, a publication of the American Association of the Advancement of Science, reported on a study looking at provider attitudes toward PrEP. Among the findings: providers do not see an increase of risky behavior among patients who take PrEP.

April 26, 2017
Subscribe to RSS - PrEP